The firm has launched a multiplex real-time PCR assay that detects HPV 16, HPV 18, and a pool of 12 other high-risk HPV subtypes.
The test runs on the BD Viper LT system and detects 14 high-risk types of human papilloma virus.
The firm also announced the appointment of new board members as it heads toward commercialization of a portable MDx platform.
BGI is also developing sequencing-based self-sampling assays for pharmacogenomics and hereditary cancer testing.
The sequencing-based, laboratory-developed test, called SmartJane, contains the first commercially available vaginal microbiome assay.
The test is performed on the company's AmpiProbe platform, and the approval expands Enzo's offering of infectious disease tests in New York.
In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.
The group is proposing women ages 30 to 65 be screened with cervical cytology every three years or receive testing for high-risk HPV every five years.
A new genome sequence study suggests sequence conservation is more common in HPV16 isolates from individuals with cancer or pre-cancerous conditions.
Medcis Pathlabs and its associates and attendees will buy Co-Diagnostics' tests for hepatitis B, hepatitis C, HIV, and human papillomavirus.
Mice in New York harbor both antibiotic-resistant bacteria and novel viruses, according to a new analysis of their fecal microbiomes.
Human Heredity and Health in Africa Initiative has issued guidelines for genomic research in the region, according to Nature News.
The Associated Press reports that an ethicist predicts that prenatal diagnosis and other advances will lead to more choices being available to prospective parents.
In Genome Biology this week: approach to analyze alternative polyadenylation, algorithm to predict transcriptomic structural variations, and more.
